行情

FGEN

FGEN

纤维蛋白原
NASDAQ

实时行情|Nasdaq Last Sale

45.03
-0.12
-0.27%
已收盘, 16:00 08/11 EDT
开盘
45.39
昨收
45.15
最高
46.20
最低
44.60
成交量
65.02万
成交额
--
52周最高
48.95
52周最低
22.65
市值
40.12亿
市盈率(TTM)
-12.7106
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测FGEN价格均价为60.88,最高价位84.00,最低价为44.00。

EPS

FGEN 新闻

更多
FibroGen Announces First Patient Enrolled In Pamrevlumab Phase 3 Clinical Trial In Patients With Duchenne Muscular Dystrophy
SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab orplacebo in combination
Benzinga · 22小时前
FibroGen EPS misses by $0.39, misses on revenue
FibroGen (NASDAQ:FGEN): Q2 GAAP EPS of -$0.95 misses by $0.39. Revenue of $42.89M (-77.6% Y/Y) misses by $5.4M. Press Release
seekingalpha · 5天前
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
finviz · 5天前
FibroGen Reports Second Quarter 2020 Financial Results
finviz · 5天前
FibroGen Announces New Appointments to its Board of Directors
finviz · 5天前
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
FibroGen to Report Second Quarter 2020 Financial Results
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00
GlobeNewswire · 07/23 11:00
Did Hedge Funds Make The Right Call On FibroGen Inc (FGEN) ?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 07/17 19:31

所属板块

生物技术和医学研究
-2.24%
制药与医学研究
-0.89%

热门股票

代码
价格
涨跌幅

FGEN 简况

FibroGen, Inc.是一家科研型生物制药公司。该公司探索、开发和商业化新型治疗方法,以解决严重的未满足的医疗需求问题。该公司的首款候选药物是roxadustat(FG-4592)。该公司也开发其他候选药物,例如FG-6874、FG-3019和FG-5200。FG-4592是一种缺氧诱导因子-脯氨酰羟化酶(HIF-PH)的口服小分子抑制剂,它通过刺激人体生成红细胞的自然途径抑制缺氧诱导因子。FG-4592正处于III期临床开发阶段,用于治疗慢性肾脏疾病诱发的贫血。FG-3019是一种单克隆抗体,该候选药物正处于II期临床开发阶段,用于治疗特发性肺纤维化(IPF)、胰腺癌、杜氏肌营养不良(DMD)和肝纤维化。FG-6874处于I期临床试验阶段。FG-5200是一种角膜移植医疗配件,该候选药物目前正处于临床前实验阶段。
展开

微牛提供FibroGen Inc(NASDAQ-FGEN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的FGEN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易FGEN股票基本功能。